CellaVision ABCVLLY +12.06%69 Interest Coverage is 62.43 as of Mar. 2026, which is 31% below its 10-year median of 90.71. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 468 Medical Devices & Instruments companies, CellaVision AB ranks better than 60.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. CellaVision AB's
Operating Income
for the
three
months ended in Mar. 2026 was $3.06 Mil. CellaVision AB's Interest Expense for the
three
months ended in Mar. 2026 was $-0.05 Mil.
CellaVision AB's interest coverage for the quarter that ended in Mar. 2026 was 62.43.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for CellaVision AB's Interest Coverage or its related term are showing as below:
CVLLY'
s Interest Coverage Range Over the Past 10 Years
Min: 29.18 Med: 90.71 Max: 2004.54
Current: 29.18
CVLLY's Interest Coverage is ranked better than 60.68% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 15.71
vs CVLLY: 29.18
CellaVision AB (OTCPK:CVLLY) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
CellaVision AB Interest Coverage Related Terms
CellaVision AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CVLLY vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, CellaVision AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a Interest Coverage of 62.43 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CellaVision AB and its competitors. This is 31% below median its historical median of 90.71. Over the past decade, CellaVision AB's Interest Coverage has ranged from 29.18 to 2,004.54. According to the industry distribution chart, CellaVision AB ranks #184 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 39.3%.
Is CellaVision AB's Interest Coverage too high?
CellaVision AB's current Interest Coverage of 62.43 is 31% below median its 10-year median of 90.71. Over the past 10 years, this metric has ranged from a low of 29.18 to a high of 2,004.54. The Medical Devices & Instruments industry median Interest Coverage is 15.71. CellaVision AB's value of 62.43 is 297.4% above this industry median. Based on the distribution chart, CellaVision AB ranks #184 out of 468 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #184 out of 468 companies for Interest Coverage. This puts CellaVision AB in the upper half of its industry. The industry median Interest Coverage is 15.71. CellaVision AB's value of 62.43 is 297.4% above this benchmark. Historically, CellaVision AB's own Interest Coverage has ranged from 29.18 to 2,004.54 over the past decade. While the company's 10-year median is 90.71 vs. the industry median of 15.71, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.71, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Interest Coverage of 62.43 is 297.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Interest Coverage is 62.43, which is 31% below median its own 10-year median of 90.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Interest Coverage is 62.43, which is 31% below median its 10-year median of 90.71 and 297.4% above the Medical Devices & Instruments industry median of 15.71. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Interest Coverage is 62.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Interest Coverage: 62.43 (31% below median its 10-year median of 90.71)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 297.4% above the Medical Devices & Instruments median (#184 of 468)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
